Q3 2020 13F Holders as of 9/30/2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
115M
-
Number of holders
-
198
-
Total 13F shares, excl. options
-
87.6M
-
Shares change
-
-908K
-
Total reported value, excl. options
-
$1.61B
-
Value change
-
-$15.5M
-
Put/Call ratio
-
2.17
-
Number of buys
-
111
-
Number of sells
-
-80
-
Price
-
$18.34
Significant Holders of Coherus Oncology, Inc. - Common Stock (CHRS) as of Q3 2020
227 filings reported holding CHRS - Coherus Oncology, Inc. - Common Stock as of Q3 2020.
Coherus Oncology, Inc. - Common Stock (CHRS) has 198 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 87.6M shares
of 115M outstanding shares and own 75.91% of the company stock.
Largest 10 shareholders include BlackRock Inc. (10.2M shares), Temasek Holdings (Private) Ltd (7.38M shares), JPMORGAN CHASE & CO (4.73M shares), ALLIANCEBERNSTEIN L.P. (4.51M shares), STATE STREET CORP (4.29M shares), VANGUARD GROUP INC (3.87M shares), PERCEPTIVE ADVISORS LLC (3.64M shares), Kohlberg Kravis Roberts & Co. L.P. (3.04M shares), AMERIPRISE FINANCIAL INC (2.37M shares), and Camber Capital Management LP (2.2M shares).
This table shows the top 198 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.